We have located links that may give you full text access.
[Novel Therapy in Guillain-Barré Syndrome].
Brain and Nerve = Shinkei Kenkyū No Shinpo 2016 December
The efficacy of plasma exchange (PE) and intravenous immunoglobulin (IVIg) therapies for Guillain-Barré syndrome have been established by numerous randomized controlled trials. However, 10-20 % of GBS patients cannot walk without aid after one year from onset of the disease. Thus, new treatment is required for these intractable cases. The Japan GBS outcome study (J-GOS) has been conducted to identify clinical or biological markers that predict the prognosis of Japanese GBS patients at an early stage. In the future, we expect to provide intractable patients so predicted with novel therapy, including molecular target drugs.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app